Business Wire
12 Dec 2025, 13:30 UTC · 40w ago
Verdict
Headline takes no side. We score RCUS −0.80 across two claims — strongly bearish.
−0.80strongly bearish
More negative than 86% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Arcus Biosciences and Gilead Sciences discontinued their Phase 3 STAR-221 study due to futility.
More negative than 99% of claims this week
The Independent Data Monitoring Committee recommended discontinuing the STAR-221 study.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 95% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
3h ago
+6.9%
Price is moving against the score
$26.87 vs $25.14 close before publication (Dec 11) · not market-adjusted
RCUS chart →